John Bridgewater

John Bridgewater at University College London led the pivotal ABC-02 trial that established gemcitabine plus cisplatin as standard first-line treatment for advanced biliary tract cancer, a landmark that defined the field for over a decade. His ongoing research has focused on the molecular characterization of intrahepatic cholangiocarcinoma and identifying actionable genomic drivers. He has been central to UK and European biliary cancer research networks and has contributed to multiple successive clinical trials building on the gemcitabine-cisplatin backbone. His work on second-line therapy and biomarker-guided approaches continues to advance BTC treatment.